Sensitivity of Medicare Claims Data for Measuring Use of Standard Multiagent Chemotherapy Regimens
暂无分享,去创建一个
[1] C. Ko,et al. The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States , 2008, Annals of Surgical Oncology.
[2] E. Van Cutsem,et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Herndon,et al. A Phase III Trial Evaluating the Combination of Cisplatin, Etoposide, and Radiation Therapy With or Without Tamoxifen in Patients With Limited-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study (9235) , 2005, American journal of clinical oncology.
[4] Xianglin L. Du,et al. External Validation of Medicare Claims for Breast Cancer Chemotherapy Compared With Medical Chart Reviews , 2006, Medical care.
[5] E. Lamont,et al. Evaluation of trends in the cost of initial cancer treatment. , 2008, Journal of the National Cancer Institute.
[6] Gregory S. Cooper,et al. Studying Radiation Therapy Using SEER-Medicare-Linked Data , 2002, Medical care.
[7] John D. Roberts,et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. , 2005, Journal of the National Cancer Institute.
[8] L. Norton,et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[10] G. Cooper,et al. Use of SEER-Medicare Data for Measuring Cancer Surgery , 2002, Medical care.
[11] E. Lamont,et al. Utility of administrative claims data for the study of brain metastases: a validation study , 2009, Journal of Neuro-Oncology.
[12] Harlan M Krumholz,et al. Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.
[13] James M. Hatten. Medicare's Common Denominator: The Covered Population , 1980, Health care financing review.
[14] C. Gross,et al. Enrollment of older persons in cancer trials after the medicare reimbursement policy change. , 2005, Archives of internal medicine.
[15] R. Marks,et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. , 2005, Journal of Clinical Oncology.
[16] R. Goldberg,et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Holland,et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.